MediWound Launches Underwritten Share Offering With H.C. Wainwright; Terms Unpriced
MDWD is trading near its 52-week low of $11.8 (13% above the low).
Summary
MediWound launched an underwritten ordinary-share offering through H.C. Wainwright with pricing and share count still blank, a raise that follows a cash balance decline to about $28.4 million at September 30, 2026 from $53.6 million at year-end 2025.
Updates
· GlobeNewswire — MediWound priced the offering of 1,200,000 ordinary shares at $12.50 per share for about $15 million gross, with a 30-day option for 180,000 more shares.
Key Events · Financing and Capital Events · MDWD
-
Underwritten Offering Launched, Unpriced
Preliminary prospectus supplement dated November 3, 2026 for an underwritten offering of ordinary shares through H.C. Wainwright; share count, public offering price and proceeds are left blank, plus a 30-day option for up to 15% additional shares.
-
Cash Fell to $28.4M
Cash, cash equivalents and deposits totaled approximately $28.4 million at September 30, 2026 versus $53.6 million at year-end 2025, and Q3 2026 revenue is expected at about $3.6 million versus $5.4 million a year ago.
-
Overhang From Warrants and Options
2,125,828 warrants at $13.475 or $15.31 per share remain outstanding (the $13.475 tranche expires November 27, 2026), alongside 1,479,362 options at a $15.79 weighted-average strike and 53,394 RSUs as of September 30, 2026.
-
Proceeds for Working Capital
Net proceeds are earmarked for working capital and general corporate purposes, with management retaining broad discretion; the company and its directors and officers are locked up for 60 days.
Analysis · MDWD · Life Sciences
MediWound is raising equity through an underwritten offering led by H.C. Wainwright, and the preliminary prospectus leaves the share count and price blank, so the size of the raise is not yet known. The timing is driven by cash: cash, equivalents and deposits fell to about $28.4 million at September 30, 2026 from $53.6 million at year-end 2025, while Q3 revenue slipped to roughly $3.6 million from $5.4 million a year earlier and a chunk of expected 2026 development-services revenue tied to a planned U.S. manufacturing facility remains uncertain. Existing holders face dilution at whatever discount the deal prices, on top of 2.13 million warrants struck at $13.475 that expire November 27, 2026 and 1.48 million options at a $15.79 weighted-average strike. Proceeds are earmarked for working capital and general corporate purposes, so the cash extends runway but does not retire debt or fund a specific catalyst.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDWD was trading at $13.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.9M. The 52-week trading range was $11.80 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.